We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Esperion sold by Pfizer; closes $55.8mm Series A round
03 May 2013
Executive Summary
After acquiring Esperion Therapeutics (cardiovascular and metabolic compounds) in 2003 for $1.25bn, Pfizer has now decided to spin off the company to a syndicate of investors. Esperion has simultaneously closed a tranched $22.75mm Series A venture round co-led by new investors Aisling Capital and Domain Associates, and returning backer Alta Partners, all of which contribute one member to the company's board. Arboretum Ventures also participated.
Deal Industry
Pharmaceuticals
Deal Status
Final
Deal Type
Financing
Spin-Off
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?